About oragenics - OGEN
Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Lakewood Ranch, FL.
OGEN At a Glance
Oragenics, Inc.
9015 Town Center Parkway
Lakewood Ranch, Florida 34202
| Phone | 1-813-286-7900 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -9,842,487.00 | |
| Sector | Health Technology | Employees | 3 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
OGEN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.404 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.692 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.035 |
OGEN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,280,829.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
OGEN Liquidity
| Current Ratio | 5.636 |
| Quick Ratio | 5.636 |
| Cash Ratio | 4.702 |
OGEN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -170.576 |
| Return on Equity | -243.942 |
| Return on Total Capital | -115.675 |
| Return on Invested Capital | -243.942 |
OGEN Capital Structure
| Total Debt to Total Equity | 2.745 |
| Total Debt to Total Capital | 2.672 |
| Total Debt to Total Assets | 2.258 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |